576 related articles for article (PubMed ID: 16926278)
1. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
2. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
3. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
[TBL] [Abstract][Full Text] [Related]
4. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
[TBL] [Abstract][Full Text] [Related]
5. N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization.
Weeks JL; Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Sep; 46(36):10353-64. PubMed ID: 17696499
[TBL] [Abstract][Full Text] [Related]
6. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
Corbin JD; Beasley A; Blount MA; Francis SH
Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
[TBL] [Abstract][Full Text] [Related]
7. Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms.
Rybalkina IG; Tang XB; Rybalkin SD
Mol Pharmacol; 2010 Apr; 77(4):670-7. PubMed ID: 20086037
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil.
Corbin J; Francis S; Zoraghi R
Int J Impot Res; 2006; 18(3):251-7. PubMed ID: 16281046
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
[TBL] [Abstract][Full Text] [Related]
10. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.
Bessay EP; Zoraghi R; Blount MA; Grimes KA; Beasley A; Francis SH; Corbin JD
Front Biosci; 2007 Jan; 12():1899-910. PubMed ID: 17127429
[TBL] [Abstract][Full Text] [Related]
12. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity.
Turko IV; Francis SH; Corbin JD
Biochemistry; 1998 Mar; 37(12):4200-5. PubMed ID: 9521742
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
Zoraghi R; Corbin JD; Francis SH
J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation.
Zoraghi R; Bessay EP; Corbin JD; Francis SH
J Biol Chem; 2005 Mar; 280(12):12051-63. PubMed ID: 15677448
[TBL] [Abstract][Full Text] [Related]
15. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
Corbin JD; Francis SH
Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
[TBL] [Abstract][Full Text] [Related]
16. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain.
Rybalkin SD; Rybalkina IG; Shimizu-Albergine M; Tang XB; Beavo JA
EMBO J; 2003 Feb; 22(3):469-78. PubMed ID: 12554648
[TBL] [Abstract][Full Text] [Related]
17. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH
Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347
[TBL] [Abstract][Full Text] [Related]
18. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
19. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.
Corbin JD; Beasley A; Blount MA; Francis SH
Biochem Biophys Res Commun; 2005 Sep; 334(3):930-8. PubMed ID: 16023993
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum.
Lau LC; Adaikan PG
Eur J Pharmacol; 2006 Jul; 541(3):184-90. PubMed ID: 16777087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
